3ddimation的个人主页 - 老虎社区

3ddimation

3ddimation

暂无个人介绍

IP属地：未知

12关注

7粉丝

0主题

0勋章

2021-12-20

Oh yea

抱歉，原内容已删除

2021-11-16

Woohoo

抱歉，原内容已删除

2021-11-07

Oh yea

抱歉，原内容已删除

2021-10-21

Nice

3 Biotech Stocks That Are Ridiculously Overpriced

2021-10-14

Wow

Singapore's central bank tightens policy in surprise move

2021-10-14

Nice

抱歉，原内容已删除

2021-10-07

Nice

Lordstown Motors shares tumbled nearly 10% in early trading

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3581487670584964,"uuid":"3581487670584964","gmtCreate":1618393820114,"gmtModify":1618463851994,"name":"3ddimation","pinyin":"3ddimation","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":12,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":693959747,"gmtCreate":1639963517260,"gmtModify":1639963517376,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh yea","listText":"Oh yea","text":"Oh yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693959747","repostId":"693959803","repostType":1,"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871390727,"gmtCreate":1637023798467,"gmtModify":1637023798562,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Woohoo","listText":"Woohoo","text":"Woohoo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871390727","repostId":"871390529","repostType":1,"isVote":1,"tweetType":1,"viewCount":630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842765090,"gmtCreate":1636246145101,"gmtModify":1636246145259,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh yea","listText":"Oh yea","text":"Oh yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842765090","repostId":"842762494","repostType":1,"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853195950,"gmtCreate":1634778288420,"gmtModify":1634778288579,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853195950","repostId":"1151911991","repostType":4,"repost":{"id":"1151911991","pubTimestamp":1634728904,"share":"https://www.laohu8.com/m/news/1151911991?lang=&edition=full","pubTime":"2021-10-20 19:21","market":"us","language":"en","title":"3 Biotech Stocks That Are Ridiculously Overpriced","url":"https://stock-news.laohu8.com/highlight/detail?id=1151911991","media":"Motley Fool","summary":"Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a sto","content":"<p>Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well priced.</p>\n<p>We asked three Motley Fool contributors which biotech stocks they think are ridiculously overpriced right now. Here's why they picked&nbsp;<b>Cassava Sciences</b>(NASDAQ:SAVA),<b>Ocugen</b>(NASDAQ:OCGN), and&nbsp;<b>Moderna</b>(NASDAQ:MRNA).</p>\n<p>This biotech isn't worth the trouble</p>\n<p><b>Prosper Junior Bakiny(Cassava Sciences):</b>Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%. It's still barely into the realm of mid-cap status, though, with a market cap of roughly $2 billion as of this writing.</p>\n<p>Cassava Sciences is hardly worth that much, though.</p>\n<p>It's is currently developing Simufilam for the treatment of Alzheimer's disease. Positive results from a pair of clinical trials -- coupled with the&nbsp;controversial approval&nbsp;of&nbsp;<b>Biogen</b>'s Aduhelm earlier this year -- have helped the company's stock perform as well as it has this year.</p>\n<p>But there are some reasons to worry. First, many companies have tried to develop effective drugs directed at the underlying causes of Alzheimer's disease. Nearly all of them failed, even after successful phase 2 studies.</p>\n<p>Even the data from Biogen's pivotal trial for Aduhelm wasn't that convincing. That's why the Food and Drug Administration is insisting on a post-approval confirmatory study for the medicine. It could be taken off the market if it fails to prove that actually helps Alzheimer's patients.</p>\n<p>Of course, just because others failed to develop an effective treatment for this condition doesn't mean Cassava Sciences will too. The point is, investors should view even the positive results Simufilam has produced so far with a healthy dose of skepticism.</p>\n<p>Results from a 12-month open-label study of Simufilam&nbsp;weren't that impressive. Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam.&nbsp;Labaton Sucharow is representing clients with short positions in the stock, so there are some financial incentives for it to target Cassava. Still, this dark cloud will continue to hover above the biotech for a while.</p>\n<p>Add these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels.</p>\n<p><b>Ocugen is too risky to take a chance on</b></p>\n<p><b>David Jagielski(Ocugen):</b>This company became popular among retail investors this year based on the hopes that it will be the next COVID-19 vaccine stock to make it big. There's just one problem: Ocugen's success in that regard will hinge on the approval of Covaxin, which it's co-developing with Indian biotech company Bharat Biotech.</p>\n<p>Ocugen announced in June that it would pursue a Biologics License Application for its COVID-19 vaccine candidate in the U.S., based on a recommendation from the Food and Drug Administration. That involves a longer process than getting an Emergency Use Authorization, and implies that the agency may have been unwilling to grant emergency approval for the vaccine.</p>\n<p>There was more positive news last week when&nbsp;India granted Emergency Use Authorization for Covaxinto be used to inoculate children ages 2 to 18. Unfortunately, that doesn't mean anything for Ocugen -- it only shares in the profits that the vaccine makes in Canada and the U.S.</p>\n<p>But even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. The performance of the company and the stock have simply not been connected. Through the first six months of this year, Ocugen has reported&nbsp;<i>no revenue</i>. Yet its shares have risen by more than 350% year to date.</p>\n<p>The good news is that there is still hope for the business beyond just its COVID-19 vaccine. The company is moving forward on its gene-therapy treatment, OCU400, and it plans to begin clinical studies on it later this year. However, the human trials phase of OCU400's development, even if it's ultimately successful, will take years.</p>\n<p>Given its market cap of $1.6 billion, I think that investors are taking on a ton of risk by buying shares of Ocugen. My view is that this is akin to gambling onpenny stocks, except in those cases, at least, valuations can be incredibly low. In Ocugen's case, the stock may have limited upside.</p>\n<p>A great company that's just too expensive</p>\n<p><b>Keith Speights(Moderna)</b>: Most of the critiques that Prosper and David had for Cassava and Ocugen don't apply to Moderna at all. The company already has a huge blockbuster on the market with its COVID-19 vaccine. It's rolling in profits as sales for the vaccine continue to soar.</p>\n<p>Moderna even has a promising pipeline. It hopes to soon advance cytomegalovirus (CMV) vaccine candidate mRNA-1647 into late-stage testing. The company is evaluating an experimental flu vaccine in early-stage testing and hopes to develop a combination COVID-19/flu vaccine. In total, the company has 17 clinical-stage programs.</p>\n<p>I think that Moderna's messenger RNA (mRNA) platform could produce many blockbuster vaccines and therapies over the coming decades. My view is that it's a great company. However, I also think that its shares are just too expensive now.</p>\n<p>Some might point to Moderna's forward price-to-earnings multiple of 11.2 as evidence that I'm dead wrong about the stock being overvalued. However, the problem with this metric is that it only looks one year into the future. Moderna's CEO has&nbsp;predicted that the pandemic could effectively end by late 2022. If he's right, I suspect that the company's revenue and earnings could fall off significantly after that.</p>\n<p>Remember that Moderna's enormous success so far has resulted from a two-dose initial regimen of its COVID-19 vaccine. Boosters of that vaccine will only require one shot. More importantly, there's uncertainty about how frequently boosters will be needed. Governments around the world could also become more price-conscious about what they'll pay for COVID-19 vaccines in a post-pandemic environment.</p>\n<p>Perhaps things will unfold in a way that justifies Moderna's current valuation. For now, though, I think there are more outcomes that could cause this stock to fall than there are catalysts that could make it soar again.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks That Are Ridiculously Overpriced</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks That Are Ridiculously Overpriced\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-20 19:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","MRNA":"Moderna, Inc.","SAVA":"Cassava Sciences Inc"},"source_url":"https://www.fool.com/investing/2021/10/20/3-biotech-stocks-that-are-ridiculously-overpriced/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151911991","content_text":"Beauty is in the eye of the beholder -- and, in many cases, so is the appropriate valuation of a stock. One investor might view a stock as overvalued, while another investor sees it as relatively well priced.\nWe asked three Motley Fool contributors which biotech stocks they think are ridiculously overpriced right now. Here's why they picked Cassava Sciences(NASDAQ:SAVA),Ocugen(NASDAQ:OCGN), and Moderna(NASDAQ:MRNA).\nThis biotech isn't worth the trouble\nProsper Junior Bakiny(Cassava Sciences):Investors have been flocking to this clinical-stage biotech all year long, pushing its share price up by well over 600%. It's still barely into the realm of mid-cap status, though, with a market cap of roughly $2 billion as of this writing.\nCassava Sciences is hardly worth that much, though.\nIt's is currently developing Simufilam for the treatment of Alzheimer's disease. Positive results from a pair of clinical trials -- coupled with the controversial approval of Biogen's Aduhelm earlier this year -- have helped the company's stock perform as well as it has this year.\nBut there are some reasons to worry. First, many companies have tried to develop effective drugs directed at the underlying causes of Alzheimer's disease. Nearly all of them failed, even after successful phase 2 studies.\nEven the data from Biogen's pivotal trial for Aduhelm wasn't that convincing. That's why the Food and Drug Administration is insisting on a post-approval confirmatory study for the medicine. It could be taken off the market if it fails to prove that actually helps Alzheimer's patients.\nOf course, just because others failed to develop an effective treatment for this condition doesn't mean Cassava Sciences will too. The point is, investors should view even the positive results Simufilam has produced so far with a healthy dose of skepticism.\nResults from a 12-month open-label study of Simufilam weren't that impressive. Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam. Labaton Sucharow is representing clients with short positions in the stock, so there are some financial incentives for it to target Cassava. Still, this dark cloud will continue to hover above the biotech for a while.\nAdd these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels.\nOcugen is too risky to take a chance on\nDavid Jagielski(Ocugen):This company became popular among retail investors this year based on the hopes that it will be the next COVID-19 vaccine stock to make it big. There's just one problem: Ocugen's success in that regard will hinge on the approval of Covaxin, which it's co-developing with Indian biotech company Bharat Biotech.\nOcugen announced in June that it would pursue a Biologics License Application for its COVID-19 vaccine candidate in the U.S., based on a recommendation from the Food and Drug Administration. That involves a longer process than getting an Emergency Use Authorization, and implies that the agency may have been unwilling to grant emergency approval for the vaccine.\nThere was more positive news last week when India granted Emergency Use Authorization for Covaxinto be used to inoculate children ages 2 to 18. Unfortunately, that doesn't mean anything for Ocugen -- it only shares in the profits that the vaccine makes in Canada and the U.S.\nBut even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. The performance of the company and the stock have simply not been connected. Through the first six months of this year, Ocugen has reported no revenue. Yet its shares have risen by more than 350% year to date.\nThe good news is that there is still hope for the business beyond just its COVID-19 vaccine. The company is moving forward on its gene-therapy treatment, OCU400, and it plans to begin clinical studies on it later this year. However, the human trials phase of OCU400's development, even if it's ultimately successful, will take years.\nGiven its market cap of $1.6 billion, I think that investors are taking on a ton of risk by buying shares of Ocugen. My view is that this is akin to gambling onpenny stocks, except in those cases, at least, valuations can be incredibly low. In Ocugen's case, the stock may have limited upside.\nA great company that's just too expensive\nKeith Speights(Moderna): Most of the critiques that Prosper and David had for Cassava and Ocugen don't apply to Moderna at all. The company already has a huge blockbuster on the market with its COVID-19 vaccine. It's rolling in profits as sales for the vaccine continue to soar.\nModerna even has a promising pipeline. It hopes to soon advance cytomegalovirus (CMV) vaccine candidate mRNA-1647 into late-stage testing. The company is evaluating an experimental flu vaccine in early-stage testing and hopes to develop a combination COVID-19/flu vaccine. In total, the company has 17 clinical-stage programs.\nI think that Moderna's messenger RNA (mRNA) platform could produce many blockbuster vaccines and therapies over the coming decades. My view is that it's a great company. However, I also think that its shares are just too expensive now.\nSome might point to Moderna's forward price-to-earnings multiple of 11.2 as evidence that I'm dead wrong about the stock being overvalued. However, the problem with this metric is that it only looks one year into the future. Moderna's CEO has predicted that the pandemic could effectively end by late 2022. If he's right, I suspect that the company's revenue and earnings could fall off significantly after that.\nRemember that Moderna's enormous success so far has resulted from a two-dose initial regimen of its COVID-19 vaccine. Boosters of that vaccine will only require one shot. More importantly, there's uncertainty about how frequently boosters will be needed. Governments around the world could also become more price-conscious about what they'll pay for COVID-19 vaccines in a post-pandemic environment.\nPerhaps things will unfold in a way that justifies Moderna's current valuation. For now, though, I think there are more outcomes that could cause this stock to fall than there are catalysts that could make it soar again.","news_type":1},"isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825005268,"gmtCreate":1634175207414,"gmtModify":1634175207414,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825005268","repostId":"1123802574","repostType":4,"repost":{"id":"1123802574","pubTimestamp":1634171544,"share":"https://www.laohu8.com/m/news/1123802574?lang=&edition=full","pubTime":"2021-10-14 08:32","market":"sg","language":"en","title":"Singapore's central bank tightens policy in surprise move","url":"https://stock-news.laohu8.com/highlight/detail?id=1123802574","media":"Reuters","summary":"SINGAPORE, Oct 14 (Reuters) - Singapore's central bank unexpectedly tightened its monetary policy on","content":"<p>SINGAPORE, Oct 14 (Reuters) - Singapore's central bank unexpectedly tightened its monetary policy on Thursday, saying the move will ensure price stability over the medium-term.</p>\n<p>The Monetary Authority of Singapore (MAS) manages monetary policy through exchange rate settings, rather than interest rates, letting the Singapore dollar rise or fall against the currencies of its main trading partners within an undisclosed band.</p>\n<p>It adjusts its policy via three levers: the slope, mid-point and width of the policy band, known as the Nominal Effective Exchange Rate, or S$NEER.</p>\n<p>The MAS said on Thursday it would raise slightly the slope of the policy band, from zero percent previously. The width of the band and the level at which it is centred will be unchanged, it said.</p>\n<p>\"This appreciation path for the S$NEER policy band will ensure price stability over the medium term while recognising the risks to the economic recovery,\" the MAS said in its statement. It said core inflation is expected to rise to 1–2% next year, and close to 2% in the medium-term.</p>\n<p>The Singapore dollar jumped about 0.3% after the announcement to hit a three-week high of S$1.3475 per dollar.</p>\n<p>Eleven of 13 economists polled by Reuters&nbsp;had forecast&nbsp;the MAS would keep its policy unchanged, while only two had expected a slight tightening.</p>\n<p>\"The economic and inflation assessment sounds definitely more sanguine for 2022 and it looks like they are focusing on cost pressures including labour costs, both domestic and imported,\" said Selena Ling, Head of Treasury Research &amp; Strategy, OCBC Bank.</p>\n<p>\"Also surprising is that they have dropped all the caveats about downside risks apart from a brief phrase on the emergence of a vaccine-resistant virus strain or severe global economic stresses.\"</p>\n<p>Separate preliminary data on Thursday showed Singapore's economy grew 6.5% in the third quarter, broadly in line with economists' forecast.</p>\n<p>The MAS said GDP growth was expected to be 6–7% this year and register a slower but still-above trend pace in 2022.</p>","source":"lsy1601381805984","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore's central bank tightens policy in surprise move</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore's central bank tightens policy in surprise move\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 08:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/world/asia-pacific/singapore-central-bank-tightens-policy-surprise-move-2021-10-14/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SINGAPORE, Oct 14 (Reuters) - Singapore's central bank unexpectedly tightened its monetary policy on Thursday, saying the move will ensure price stability over the medium-term.\nThe Monetary Authority ...</p>\n\n<a href=\"https://www.reuters.com/world/asia-pacific/singapore-central-bank-tightens-policy-surprise-move-2021-10-14/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.reuters.com/world/asia-pacific/singapore-central-bank-tightens-policy-surprise-move-2021-10-14/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123802574","content_text":"SINGAPORE, Oct 14 (Reuters) - Singapore's central bank unexpectedly tightened its monetary policy on Thursday, saying the move will ensure price stability over the medium-term.\nThe Monetary Authority of Singapore (MAS) manages monetary policy through exchange rate settings, rather than interest rates, letting the Singapore dollar rise or fall against the currencies of its main trading partners within an undisclosed band.\nIt adjusts its policy via three levers: the slope, mid-point and width of the policy band, known as the Nominal Effective Exchange Rate, or S$NEER.\nThe MAS said on Thursday it would raise slightly the slope of the policy band, from zero percent previously. The width of the band and the level at which it is centred will be unchanged, it said.\n\"This appreciation path for the S$NEER policy band will ensure price stability over the medium term while recognising the risks to the economic recovery,\" the MAS said in its statement. It said core inflation is expected to rise to 1–2% next year, and close to 2% in the medium-term.\nThe Singapore dollar jumped about 0.3% after the announcement to hit a three-week high of S$1.3475 per dollar.\nEleven of 13 economists polled by Reuters had forecast the MAS would keep its policy unchanged, while only two had expected a slight tightening.\n\"The economic and inflation assessment sounds definitely more sanguine for 2022 and it looks like they are focusing on cost pressures including labour costs, both domestic and imported,\" said Selena Ling, Head of Treasury Research & Strategy, OCBC Bank.\n\"Also surprising is that they have dropped all the caveats about downside risks apart from a brief phrase on the emergence of a vaccine-resistant virus strain or severe global economic stresses.\"\nSeparate preliminary data on Thursday showed Singapore's economy grew 6.5% in the third quarter, broadly in line with economists' forecast.\nThe MAS said GDP growth was expected to be 6–7% this year and register a slower but still-above trend pace in 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825002522,"gmtCreate":1634175149833,"gmtModify":1634175149934,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825002522","repostId":"825002356","repostType":1,"isVote":1,"tweetType":1,"viewCount":570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823907725,"gmtCreate":1633569389811,"gmtModify":1633569484454,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823907725","repostId":"1119543656","repostType":4,"repost":{"id":"1119543656","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633441633,"share":"https://www.laohu8.com/m/news/1119543656?lang=&edition=full","pubTime":"2021-10-05 21:47","market":"us","language":"en","title":"Lordstown Motors shares tumbled nearly 10% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1119543656","media":"Tiger Newspress","summary":"Lordstown Motors shares tumbled nearly 10% in early trading.\nLordstown stock price target cut to $2 ","content":"<p>Lordstown&nbsp;Motors&nbsp;shares&nbsp;tumbled&nbsp;nearly&nbsp;10%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ebbd6c982020852662b75eba0d0a3ab1\" tg-width=\"878\" tg-height=\"618\" referrerpolicy=\"no-referrer\">Lordstown stock price target cut to $2 from $8 at&nbsp;Morgan Stanley.</p>\n<p>Morgan Stanley lowers Lordstown Motors Corp.&nbsp;to an Underperform rating from Equal-weight after a significant reset of its forecasts and valuation as it factored in last week's update from the electric vehicle maker.</p>\n<p>Analyst Adam Jonas: \"While the agreement with Foxconn helps secure the future of the Lordstown plant and buys time to explore other business opportunities for RIDE (new programs,new platforms,&nbsp;new segments that&nbsp;have yet to be developed), we believe there would likely be little left for shareholders.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lordstown Motors shares tumbled nearly 10% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLordstown Motors shares tumbled nearly 10% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-05 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Lordstown&nbsp;Motors&nbsp;shares&nbsp;tumbled&nbsp;nearly&nbsp;10%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/ebbd6c982020852662b75eba0d0a3ab1\" tg-width=\"878\" tg-height=\"618\" referrerpolicy=\"no-referrer\">Lordstown stock price target cut to $2 from $8 at&nbsp;Morgan Stanley.</p>\n<p>Morgan Stanley lowers Lordstown Motors Corp.&nbsp;to an Underperform rating from Equal-weight after a significant reset of its forecasts and valuation as it factored in last week's update from the electric vehicle maker.</p>\n<p>Analyst Adam Jonas: \"While the agreement with Foxconn helps secure the future of the Lordstown plant and buys time to explore other business opportunities for RIDE (new programs,new platforms,&nbsp;new segments that&nbsp;have yet to be developed), we believe there would likely be little left for shareholders.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119543656","content_text":"Lordstown Motors shares tumbled nearly 10% in early trading.\nLordstown stock price target cut to $2 from $8 at Morgan Stanley.\nMorgan Stanley lowers Lordstown Motors Corp. to an Underperform rating from Equal-weight after a significant reset of its forecasts and valuation as it factored in last week's update from the electric vehicle maker.\nAnalyst Adam Jonas: \"While the agreement with Foxconn helps secure the future of the Lordstown plant and buys time to explore other business opportunities for RIDE (new programs,new platforms, new segments that have yet to be developed), we believe there would likely be little left for shareholders.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":825005268,"gmtCreate":1634175207414,"gmtModify":1634175207414,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825005268","repostId":"1123802574","repostType":4,"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823907725,"gmtCreate":1633569389811,"gmtModify":1633569484454,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823907725","repostId":"1119543656","repostType":4,"isVote":1,"tweetType":1,"viewCount":569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693959747,"gmtCreate":1639963517260,"gmtModify":1639963517376,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh yea","listText":"Oh yea","text":"Oh yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693959747","repostId":"693959803","repostType":1,"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871390727,"gmtCreate":1637023798467,"gmtModify":1637023798562,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Woohoo","listText":"Woohoo","text":"Woohoo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871390727","repostId":"871390529","repostType":1,"isVote":1,"tweetType":1,"viewCount":630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842765090,"gmtCreate":1636246145101,"gmtModify":1636246145259,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh yea","listText":"Oh yea","text":"Oh yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842765090","repostId":"842762494","repostType":1,"isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853195950,"gmtCreate":1634778288420,"gmtModify":1634778288579,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853195950","repostId":"1151911991","repostType":4,"isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825002522,"gmtCreate":1634175149833,"gmtModify":1634175149934,"author":{"id":"3581487670584964","authorId":"3581487670584964","name":"3ddimation","avatar":"https://static.tigerbbs.com/ffc0ec3def620c9a38ce2f700c72864a","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825002522","repostId":"825002356","repostType":1,"isVote":1,"tweetType":1,"viewCount":570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}